{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T11:41:54Z","timestamp":1772710914600,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005296","name":"Universit\u00e4tsklinikum Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Lasting local control of brain metastases following stereotactic radiotherapy is becoming increasingly relevant since systemic treatment constantly improves the prognosis of patients with extracranial metastases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>73 patients with 103 brain metastases received hypofractionated stereotactic radiotherapy (FSRT) in 6 fractions of 5\u00a0Gy between January 2017 and December 2021 at the University Hospital Regensburg, Germany. The study retrospectively evaluated local progression free survival (LPFS), overall survival (OS) and distant brain progression free survival (DPFS) of patients without prior radiotherapy of the brain. Response rate and brain radiation necrosis were reported. Cox proportional hazard models evaluated prognostic factors of OS and LPFS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median patient age was 61.0 years (Interquartile range, IQR 51.0, 67.5). The most common tumor types were malignant melanoma (34.2%) and non-small cell lung adenocarcinoma (26.0%). The median gross tumor volume (GTV) was 0.9\u00a0cm\u00b3 (IQR 0.4, 3.6). The median follow-up time of all patients was 36.3 months (95%CI 29.1, 43.4). The median OS was 17.4 months (95%CI 9.9, 24.9). Overall survival rates at 6-, 12-, 18-, 24-, and 30 months were 81.9%, 59.1%, 49.0%, 41.3%, and 37.2%, retrospectively. The mean LPFS was 38.1 months (95%CI 31.4, 44.9), while the median LPFS has not been reached. LPFS rates at 6-, 12-, 18-, 24- and 30 months were 78.9%, 68.7%, 64.3%, 61.6% and 58.7%, retrospectively. Median DPFS of all patients was 7.7 months (95%CI 6.1, 9.3). Six, 12-, 18-, 24- and 30 months DPFS rates were 62.1%, 36.3%, 31.1%, 24.8% and 21.7%. Five brain metastases (4.8%) developed brain radiation necrosis. In multivariate analysis, the number of brain metastases negatively affected LPFS. Non-melanoma and non-renal cell cancer was associated with a higher chance of LPFS in comparison to other cancer. A GTV\u2009&gt;\u20091.5\u00a0cm\u00b3 translated into a higher risk of death compared to a GTV\u2009\u2264\u20091.5\u00a0cm\u00b3 and Karnofsky performance score was predictive of OS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>FSRT in 6 fractions of 5\u00a0Gy seems to be an effective treatment with an acceptable local control for patients with brain metastases although melanoma and renal cell cancer seem to have a worse local control in comparison to other cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This study is retrospectively registered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-023-02277-6","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T11:01:44Z","timestamp":1684753304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Fractionated stereotactic radiotherapy of brain metastases: results of a retrospective study"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7435-9337","authenticated-orcid":false,"given":"Isabella","family":"Gruber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Stark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6538-9980","authenticated-orcid":false,"given":"Karin","family":"Weidner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"Treutwein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Koelbl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"issue":"11","key":"2277_CR1","first-page":"4655","volume":"32","author":"E Tabouret","year":"2012","unstructured":"Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Gon\u00e7alves A. Recent trends in epidemiology of brain metastases: an overview. Anticancer Res. 2012;32(11):4655\u201362.","journal-title":"Anticancer Res"},{"issue":"2","key":"2277_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/neuonc\/now241","volume":"19","author":"R Soffietti","year":"2017","unstructured":"Soffietti R, Abacioglu U, Baumert B, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of neuro-oncology (EANO). Neuro Oncol. 2017;19(2):162\u201374. https:\/\/doi.org\/10.1093\/neuonc\/now241","journal-title":"Neuro Oncol"},{"issue":"2","key":"2277_CR3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","volume":"47","author":"E Shaw","year":"2000","unstructured":"Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90 \u2013 05. Int J Radiat Oncol Biol Phys. 2000;47(2):291\u20138. https:\/\/doi.org\/10.1016\/S0360-3016(99)00507-6","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2277_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/JAMA.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown PD, Jaeckle K, Ballman KV, et al. Effect of Radiosurgery alone vs Radiosurgery with Whole Brain Radiation Therapy on cognitive function in patients with 1 to 3 brain metastases: a Randomized Clinical Trial. JAMA. 2016;316(4):401\u20139. https:\/\/doi.org\/10.1001\/JAMA.2016.9839","journal-title":"JAMA"},{"issue":"3","key":"2277_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/J.RADONC.2011.01.011","volume":"98","author":"R Wiggenraad","year":"2011","unstructured":"Wiggenraad R, Kanter AV, De, Kal HB, Taphoorn M, Vissers T, Struikmans H. Dose-effect relation in stereotactic radiotherapy for brain metastases. A systematic review. Radiother Oncol. 2011;98(3):292\u20137. https:\/\/doi.org\/10.1016\/J.RADONC.2011.01.011","journal-title":"Radiother Oncol"},{"issue":"1","key":"2277_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1148\/105.1.135","volume":"105","author":"RF Kallman","year":"1972","unstructured":"Kallman RF. The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology. 1972;105(1):135\u201342. https:\/\/doi.org\/10.1148\/105.1.135","journal-title":"Radiology"},{"issue":"1","key":"2277_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/neuonc\/nou284","volume":"17","author":"D Kondziolka","year":"2015","unstructured":"Kondziolka D, Shin SM, Brunswick A, Kim I, Silverman JS. The biology of radiosurgery and its clinical applications for brain tumors. Neuro Oncol. 2015;17(1):29\u201344. https:\/\/doi.org\/10.1093\/neuonc\/nou284","journal-title":"Neuro Oncol"},{"issue":"1","key":"2277_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/S11060-015-1767-4\/TABLES\/3","volume":"123","author":"BR Eaton","year":"2015","unstructured":"Eaton BR, La Riviere MJ, Kim S, et al. Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. J Neurooncol. 2015;123(1):103\u201311. https:\/\/doi.org\/10.1007\/S11060-015-1767-4\/TABLES\/3","journal-title":"J Neurooncol"},{"issue":"4","key":"2277_CR9","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","volume":"37","author":"L Gaspar","year":"1997","unstructured":"Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745\u201351. https:\/\/doi.org\/10.1016\/S0360-3016(96)00619-0","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2277_CR10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ijrobp.2009.08.025","volume":"77","author":"PW Sperduto","year":"2010","unstructured":"Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655\u201361. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.08.025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2277_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/jicru_ndx010","volume":"14","author":"7","year":"2014","unstructured":"7. Prescribing, Recording, and reporting. J Int Comm Radiat Units Meas. 2014;14(2):101\u20139. https:\/\/doi.org\/10.1093\/jicru_ndx010","journal-title":"J Int Comm Radiat Units Meas"},{"issue":"6","key":"2277_CR12","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","volume":"16","author":"NU Lin","year":"2015","unstructured":"Lin NU, Lee EQ, Aoyama H, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015;16(6):e270\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(15)70057-4","journal-title":"Lancet Oncol"},{"issue":"11","key":"2277_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00066-007-1714-1","volume":"183","author":"A Fahrig","year":"2007","unstructured":"Fahrig A, Ganslandt O, Lambrecht U, et al. Hypofractionated stereotactic radiotherapy for brain metastases: results from three different dose concepts. Strahlentherapie und Onkol. 2007;183(11):625\u201330. https:\/\/doi.org\/10.1007\/s00066-007-1714-1","journal-title":"Strahlentherapie und Onkol"},{"issue":"2\u20133","key":"2277_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000097923","volume":"85","author":"A Narayana","year":"2007","unstructured":"Narayana A, Chang J, Yenice K, et al. Hypofractionated stereotactic radiotherapy using intensity-modulated radiotherapy in patients with one or two brain metastases. Stereotact Funct Neurosurg. 2007;85(2\u20133):82\u20137. https:\/\/doi.org\/10.1159\/000097923","journal-title":"Stereotact Funct Neurosurg"},{"issue":"2","key":"2277_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/J.IJROBP.2010.05.033","volume":"81","author":"YJ Kim","year":"2011","unstructured":"Kim YJ, Cho KH, Kim JY, et al. Single-dose versus fractionated stereotactic radiotherapy for brain metastases. Int J Radiat Oncol Biol Phys. 2011;81(2):483\u20139. https:\/\/doi.org\/10.1016\/J.IJROBP.2010.05.033","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2277_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.18053\/jctres.06.202001.002","volume":"6","author":"C De La Pinta","year":"2020","unstructured":"De La Pinta C, Fern\u00e1ndez-Lizarbe E, Sevillano D, et al. Brain metastases: single-dose radiosurgery versus hypofractionated stereotactic radiotherapy: a retrospective study. J Clin Transl Res. 2020;6(1):6\u201313. https:\/\/doi.org\/10.18053\/jctres.06.202001.002","journal-title":"J Clin Transl Res"},{"key":"2277_CR17","doi-asserted-by":"publisher","unstructured":"Fokas E, Henzel M, Surber G, Kleinert G, Hamm K, Engenhart-Cabillic R. Stereotactic radiosurgery and fractionated stereotactic radiotherapy: comparison of efficacy and toxicity in 260 patients with brain metastases. https:\/\/doi.org\/10.1007\/s11060-012-0868-6","DOI":"10.1007\/s11060-012-0868-6"},{"issue":"7\u20138","key":"2277_CR18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000522645","volume":"45","author":"A Piras","year":"2022","unstructured":"Piras A, Boldrini L, Menna S, et al. Five-fraction stereotactic radiotherapy for Brain Metastases: a Single-Institution experience on different dose schedules. Oncol Res Treat. 2022;45(7\u20138):408\u201314. https:\/\/doi.org\/10.1159\/000522645","journal-title":"Oncol Res Treat"},{"key":"2277_CR19","doi-asserted-by":"publisher","unstructured":"Lesueur P, Lequesne J, Barraux V, et al. Radiosurgery or hypofractionated stereotactic radiotherapy for brain metastases from radioresistant primaries (melanoma and renal cancer). Radiat Oncol. 2018;13(1). https:\/\/doi.org\/10.1186\/s13014-018-1083-1","DOI":"10.1186\/s13014-018-1083-1"},{"issue":"2","key":"2277_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11060-014-1388-3","volume":"117","author":"G Minniti","year":"2014","unstructured":"Minniti G, D\u2019Angelillo RM, Scaringi C, et al. Fractionated stereotactic radiosurgery for patients with brain metastases. J Neurooncol. 2014;117(2):295\u2013301. https:\/\/doi.org\/10.1007\/s11060-014-1388-3","journal-title":"J Neurooncol"},{"issue":"1","key":"2277_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.radonc.2006.08.024","volume":"81","author":"A Ernst-Stecken","year":"2006","unstructured":"Ernst-Stecken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G. Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: results and toxicity. Radiother Oncol. 2006;81(1):18\u201324. https:\/\/doi.org\/10.1016\/j.radonc.2006.08.024","journal-title":"Radiother Oncol"},{"issue":"4","key":"2277_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","volume":"30","author":"PW Sperduto","year":"2012","unstructured":"Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419\u201325. https:\/\/doi.org\/10.1200\/JCO.2011.38.0527","journal-title":"J Clin Oncol"},{"issue":"5","key":"2277_CR23","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/S0360-3016(01)01696-0","volume":"51","author":"E Weltman","year":"2001","unstructured":"Weltman E, Salvajoli JV, Brandt RA, et al. Radiosurgery for brain metastases: who may not benefit? Int J Radiat Oncol. 2001;51(5):1320\u20137. https:\/\/doi.org\/10.1016\/S0360-3016(01)01696-0","journal-title":"Int J Radiat Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02277-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-023-02277-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02277-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T11:06:18Z","timestamp":1684753578000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-023-02277-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2277"],"URL":"https:\/\/doi.org\/10.1186\/s13014-023-02277-6","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"assertion":[{"value":"11 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the local Ethics Board of the University of Regensburg (Ethics approval number: 22-2868-104). The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}